PLAT and COVID-19: Doughnut pie chart depicting from innermost to outermost—Circle 1: ICU patient cohorts, including sepsis, COVID-19 or both conditions; Circle 2: Study design, including prospective, validation, case report, poster, letter; Circle 3: Fibrinolysis activator and concentration used, including tissue plasminogen activator (tPA; μg/mL) and Urokinase (Urok; U/mL); Circle 4: Frequency and timing of FE-VET relative to ICU admission, with early (0–3 days) and late (> 3 days); Circle 5: Study outcomes, including clinical, biomarkers or interventional